Development of a pan-betacoronavirus vaccine

Document text

Principal Investigator: Florian  Krammer
Organization: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Fiscal Year: 2023
Award: $612,607
Funding agency: National Institute of Allergy and Infectious Diseases

The SARS-CoV-2 pandemic represents an exceptional public health crisis highlighting the need for better
understanding of the mechanisms controlling broadly protective immune responses and generating vaccine
candidates able to elicit such responses. The program project entitled “Programming Long-lasting Immunity
to Coronaviruses (PLUTO)” proposes a comprehensive research plan towards designing pan-sarbecovirus
and pan-betacoronavirus vaccines with broad protection by applying in-depth B cell characterization in the
context of coronavirus immune histories imprinted by successive vaccinations and/or infections. Two
complementary research projects will establish correlates of robust, durable and protective coronavirus
humoral immunity (Project 1) as well as design and test efficacy of viral variant-proof pan-sarbecovirus and
pan-betacoronavirus vaccines (Project 2). The Cores will synergize with the two research projects to support
successful completion of research aims and the long-term goal of the project. The Administrative Core will
manage the consortium, coordinate cross-project activities, and create the structure and environment needed
to accomplish PLUTO's goals. The Antibody Core will develop a large panel of recombinant monoclonal
antibodies against coronavirus spike proteins to aid in defining specificity of immune responses elicited by
coronavirus infection and/or vaccination in humans and animal models. The Animal Model Core will provide a
central resource with approvals, facilities, and expertise to assess efficacy of broadly cross-reactive
coronavirus antibodies and vaccines in robust pre- The Research Projects will collaborate with each other
with the support of the services provided by Antibody and Animal Model Cores and overall coordination by
the Administrative Core. Project 2 will focus on the development and design of variant-proof pan-
sarbecovirus vaccines as well as pan-betacoronavirus vaccines clinical models against a spectrum of
coronaviruses, including Select Agents. A multidisciplinary team of scientists from five institutions who have an
outstanding track record of working collaboratively will conduct the proposed studies. The integrated and
synergistic activities across Projects and Cores will drive successful completion of the program project's
ambitious research agenda, enabling achievement of the long-term PLUTO goal of developing viral variant-
proof pan-sarbecovirus and pan-betacoronavirus vaccines. These findings will contribute to curbing the
current SARS-CoV-2 pandemic and help to mitigate the risk of future pandemics with coronaviruses.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><Achievement><Achievement Attainment><Administrative Coordination><Animal Model><Animal Models and Related Studies><Animals><Antibodies><Antibody Response><Antigenic Determinants><Antigens><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><B.1.1.529><B.1.351><B.1.617.2><Binding><Binding Determinants><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 S protein><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus infection><COVID19 S protein><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 public health crisis><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 vaccine><COVID19 virus><Clinical><Clinical Treatment Moab><CoV S protein><CoV glycoprotein S><CoV spike glycoprotein><CoV spike protein><CoV-2><CoV2><Collaborations><Coronaviridae><Coronaviridae Infections><Coronavirus><Coronavirus Infections><Coronavirus glycoprotein S><Coronavirus spike protein><Cross Reactions><Delta variant><Development><Disease><Disease Outbreaks><Disorder><Environment><Epidemic><Epitopes><Ferrets><Funding><Future><Goals><History><Human><Humoral Immunities><Immune><Immune response><Immunes><Immunity><Immunological response><Infection><Institution><Knowledge><Learning><MERS corona virus><MERS coronavirus><MERS virus><MERS-CoV><Messenger RNA><Methodology><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome-CoV><Middle East Respiratory coronavirus><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome-CoV><Modeling><Modern Man><Molecular Interaction><Monoclonal Antibodies><NIAID><National Institute of Allergy and Infectious Disease><Omicron variant><Outbreaks><Pathogenicity><Phenotype><Population><Preparedness><Proteins><Public Health><R-Series Research Projects><R01 Mechanism><R01 Program><Readiness><Recombinants><Recording of previous events><Regimen><Research><Research Grants><Research Project Grants><Research Projects><Research Resources><Resources><Role><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 B.1.1.529><SARS-CoV-2 B.1.351><SARS-CoV-2 B.1.617.2><SARS-CoV-2 S protein><SARS-CoV-2 beta><SARS-CoV-2 delta><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 omicron><SARS-CoV-2 omicron variant><SARS-CoV-2 pandemic><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sarbecovirus><Scientist><Services><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><South Africa strain><South Africa variant><South African strain><South African variant><Specificity><Structure><Testing><Time><Update><Vaccination><Vaccine Design><Vaccines><Variant><Variation><Viral><Virus><Work><Wuhan coronavirus><Zoonoses><Zoonotic><Zoonotic Infection><antibody-based immunity><beta CoV><beta coronavirus><beta coronavirus vaccine><betaCoV><betacoronavirus><betacoronavirus vaccine><cohort><corona virus><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus S protein><coronavirus disease 2019 S protein><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus spike glycoprotein><coronavirus vaccination><cross reactivity><design><designing><determine efficacy><develop a vaccine><develop vaccines><development of a vaccine><developmental><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><efficacy testing><evaluate efficacy><examine efficacy><experience><future pandemic><hCoV19><histories><host response><human model><immune system response><immunization strategy><immunogen><immunoresponse><imprint><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><mAbs><mRNA><member><model of animal><model of human><monoclonal Abs><multidisciplinary><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><neutralizing mAb><neutralizing monoclonal antibodies><next pandemic><novel><omicron variant of COVID-19><omicron variant of SARS-CoV-2><pan CoV vaccine><pan coronavirus vaccine><panCoV vaccine><panbetaCoV vaccine><pancoronavirus vaccine><pandemic><pandemic concern><pandemic disease><pandemic potential><pandemic risk><pandemic threat><programs><rational design><receptor binding><receptor bound><response><risk mitigation><seasonal coronavirus><seasonal human coronavirus><severe acute respiratory syndrome coronavirus 2 B.1.1.529><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 B.1.617.2><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe acute respiratory syndrome-CoV><social role><spillover event><synergism><universal CoV vaccine><universal coronavirus vaccine><universal flu vaccine><universal influenza vaccine><universal influenza virus vaccine><universal vaccine against flu><universal vaccine against influenza><vaccination against coronavirus><vaccination strategy><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine development><vaccine effectiveness><vaccine for novel coronavirus><vaccine-induced immunity><vaccine-induced protection><β CoV><β coronavirus><β coronavirus vaccine><βCoV>